Krystal Biotech Stock Today
| KRYS Stock | USD 188.50 1.61 0.86% |
PerformanceOK
| Odds Of DistressVery Small
|
Krystal Biotech is selling for under 188.50 as of the 19th of March 2025; that is 0.86 percent increase since the beginning of the trading day. The stock's lowest day price was 181.03. Krystal Biotech has a very small chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of September 2017 | Category Healthcare | Classification Health Care |
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company has 28.81 M outstanding shares of which 3.19 M shares are now shorted by private and institutional investors with about 10.41 trading days to cover. More on Krystal Biotech
Moving against Krystal Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Krystal Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Founder | Suma Krishnan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKrystal Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Krystal Biotech's financial leverage. It provides some insight into what part of Krystal Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Krystal Biotech (KRYS) is traded on NASDAQ Exchange in USA. It is located in 2100 Wharton Street, Pittsburgh, PA, United States, 15203 and employs 275 people. Krystal Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.38 B. Krystal Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 28.81 M outstanding shares of which 3.19 M shares are now shorted by private and institutional investors with about 10.41 trading days to cover.
Krystal Biotech currently holds about 425.56 M in cash with 123.42 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58.
Check Krystal Biotech Probability Of Bankruptcy
Ownership AllocationThe majority of Krystal Biotech outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Krystal Biotech to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Krystal Biotech. Please pay attention to any change in the institutional holdings of Krystal Biotech as this could imply that something significant has changed or is about to change at the company.
Check Krystal Ownership Details
Krystal Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Soleus Capital Management, L.p. | 2024-12-31 | 358.4 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 304.1 K | |
| Jennison Associates Llc | 2024-12-31 | 303.5 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 277.2 K | |
| Amvescap Plc. | 2024-12-31 | 275.2 K | |
| Northern Trust Corp | 2024-12-31 | 262.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 256.3 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 243.2 K | |
| Woodline Partners Lp | 2024-12-31 | 221.1 K | |
| Fmr Inc | 2024-12-31 | 4.3 M | |
| Blackrock Inc | 2024-12-31 | 4 M |
Krystal Biotech Historical Income Statement
Krystal Stock Against Markets
Krystal Biotech Corporate Management
| Christine Wilson | Head Marketing | Profile | |
| David Chien | Senior Development | Profile | |
| Hubert MD | Senior Development | Profile | |
| Gloria Lin | Accounting Mang | Profile | |
| Kathryn Romano | Executive Officer | Profile | |
| Katherine Tuminello | HR Mang | Profile |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.